World Health Organization Issues Warning Over Severe Scarcity of Weight-Loss Jabs

Less than 10% of patients eligible to benefit from weight-loss injections such as Wegovy have access to them, states the global health agency as it publishes its initial guidance on the medications.

With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for more widespread and fairer availability to GLP-1 medication.

According to estimates, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.

"Our latest guidelines affirms that obesity is a long-term condition that can be addressed with holistic and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and distribution challenges are key hurdles to broad access to the injections that can aid individuals in losing substantial body mass, notes the body.

GLP-1 Therapy Supply Crisis

Even in the current most favorable outlook, the supply of such drugs would only suffice for about 100 million people – fewer than 10% of eligible patients, according to the health organization.

The guideline calls on nations and manufacturers to widen availability, through measures like licensing agreements.

Exclusive production rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026.

How Weight-Loss Drugs Operate

These medications replicate a natural hormone to delay gastric emptying, curb appetite and boost satiety so people eat less.

People usually see weight reduction within a few weeks of commencing the regular doses.

Research points to users may put most of the weight back on a year later of discontinuing the drug, when their usual hunger come back.

Being overweight or obese increases your likelihood for developing medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers.

Excess weight impacts individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, per the health agency.